Cure8 trial brief
A new oral investigational therapy (TAK-279) is being tested in a randomized phase 2 trial for moderate–severe ulcerative colitis. Trial results could influence future treatment options if the drug proves safe and effective.
Adults with moderately to severely active ulcerative colitis, clinicians and researchers involved in UC drug development, and patients who have had inadequate response or intolerance to prior UC therapies.
This is a registered phase 2 interventional study (TAK-279-UC-2001) with a 12-week double-blind induction period comparing two doses of TAK-279 vs placebo, followed by a 40-week open-label period where all participants may receive TAK-279. About 207–213 participants across multiple U.S. sites are planned.
The primary endpoint is clinical remission at week 12 measured by a modified Mayo score (stool frequency, rectal bleeding, endoscopic score). The study enrolls adults 18–75 with moderately to severely active UC who have had inadequate response or intolerance to prior therapies.
People with Crohn’s disease, prior ostomy/J-pouch, or certain UC complications are excluded. If you’re considering trial participation, the registry lists inclusion/exclusion criteria, study visits, dosing schema, and safety follow-up; discuss trial suitability and risks with your gastroenterologist or the study team.
This is a registered phase 2 clinical trial record (active, not recruiting) on ClinicalTrials.gov. It describes study design, eligibility, interventions, and planned outcomes but does not report results. As a trial registry entry, it should be interpreted as a plan rather than evidence of efficacy or safety.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new Phase 2 trial is testing MK-8690 as a potential subcutaneous treatment for moderate–severe ulcerative colitis, with clinical remission at 12 weeks as the primary goal. Positive results could point to an additional...
This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...
This trial tests a new oral drug, AC-101, for moderate-to-severe ulcerative colitis and may expand future treatment options if it proves effective and safe. The study targets patients who have failed or could not...
